Compare the Clinical Efficacy of 3% Diquafosol and 0.1% Hyaluronic Acid in Patients with Dry Eye After Trans-PRK

Launched by HE EYE HOSPITAL · Feb 21, 2025

Keywords

ClinConnect Summary

This clinical trial is designed to compare two treatments for dry eye symptoms that can occur after a specific type of eye surgery called Trans-PRK. The treatments being compared are 3% diquafosol and 0.1% hyaluronic acid. Both of these treatments are known to help relieve dry eye symptoms, which can affect how well a person sees and their overall satisfaction after surgery.

To take part in this study, participants need to be between 18 and 40 years old and have certain vision requirements, such as having stable eyesight for at least two years and not being overly nearsighted or having significant astigmatism. They should not currently wear contact lenses and must meet specific health criteria regarding their eye health. Those who join the trial will receive one of the two treatments and will be monitored to see which one works better in reducing dry eye symptoms after their surgery. It's important to note that this trial is not yet recruiting participants, so interested individuals will need to wait for it to start.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-40 years.
• • The refractive status should be maintained at least for more than 2 years, during which the annual increase in myopia should be controlled within 0.50 D.
• • Pherical equivalent (SE) ≤-6.00D, astigmatic power≤-2.00D.
• • Best corrected vision before surgery≥1.0.
• • Patients should stop wearing soft contact lenses for at least 2 weeks and hard contact lenses for at least 4 weeks before surgery.
• • Postoperative corneal stromal thickness was preserved (280 μm).
• Exclusion Criteria:
• • Suspected of having keratoconus, a definite diagnosis of keratoconus, or another type of corneal dilatation disease.
• • There is active inflammation or symptoms of infection in the eye.
• • The thickness of the cornea does not meet the preset cutting depth requirement: the thickness of the central cornea should be greater than 450 μm, and the thickness of the central corneal stroma remaining under the corneal flap should be maintained above 250 μm after the intended cutting (280 μm recommended).
• • Dry eye.
• • There are serious lesions in the accessory structures of the eye, such as defects or deformations of the eyelids.
• • People with uncontrolled systemic connective tissue diseases and autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis.